Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...

As part of a postmarketing requirement, Valneva will be initiating a study to assess the risk of severe chikungunya-like adverse reactions following administration of Ixchiq.

The Food and Drug Administration (FDA) has granted accelerated approval to Modeyso ™ (dordaviprone), a protease activator, for the treatment of adult and pediatric patients aged 1 year and older with ...

Watchful waiting extended as initial management strategy for all patients with uncomplicated acute bacterial rhinosinusitis ...

No significant increases seen in rate of hospital contacts for any of 29 adverse events in 28-day risk period after vaccination.

Cognitive functional therapy, with or without biofeedback, more effective than usual care for chronic disabling low back pain.

HealthDay News — Canagliflozin is associated with a clinically meaningful reduction in hemoglobin A1c (HbA1c) for children and adolescents with type 2 diabetes mellitus (T2DM), according to a study ...

Stronger differential effect for CPAP seen for those without excessive sleepiness, without increased blood pressure.

HealthDay News — Having a supratherapeutic international normalized ratio (INR) while taking warfarin does not significantly increase the risk for brain bleeding after blunt head trauma in older ...

HealthDay News — For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with nonarteritic anterior ischemic optic neuropathy (NAION), according to ...

Notable Drug Approvals.

CRS is a life-threatening condition that results in the excessive release of cytokines into the bloodstream, causing inflammation and damage to organs and tissues.